Request for Covid-19 Impact Assessment of this Report
Complete report $34,500.DataPack (test volumes, sales forecasts, supplier shares) $15,900.
Summary
This comprehensive seven-country report contains 700 pages, 250 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the global hematology and flow cytometry markets during the next five years.
The report explores business and technological trends in the US, Europe (France, Germany, Italy, Spain, UK) and Japan provides market share estimates, test volume forecasts, and instrument placements; compares features of major analyzers; profiles leading competitors and emerging market entrants; and suggests specific product and marketing opportunities facing suppliers.
Rationale
During the next five years, continued advances in molecular diagnostics, monoclonal antibodies, lasers and IT, as well as growing understanding of immunologic forces regulating systemic diseases, will have a profound impact on the hematology and flow cytometry markets worldwide. New molecular diagnostic and monoclonal antibody tests will facilitate existing procedures and provide basis for sensitive, specific and simple assays. The introduction of smaller and easy-to-operate laser systems will further expand applications of flow cytometry to routine clinical laboratories. Further advances in IT will reduce the cost of instrument manufacture, service warranty, and permit development of self-troubleshooting, autocalibration and other advanced features. Presently tedious analyses of chromosomal abnormalities, DNA content, and lymphocyte subsets will become more automated and routine.
Hematology Tests
CBC + 5-Part Differential, Manual Differential/Review, Hematocrit (Automated, Manual),
Hemoglobin (Automated, Manual), Sedimentation Rate, Reticulocytes, WBC (Automated, Manual),
Platelets (Automated, Manual), Bone Marrow Analysis, RBC, Eosinophils.
Flow Cytometry Tests
Cell Surface Markers (CD4/CD8/T&B Lymphocytes, CD34, Others), Chemotherapy Monitoring (Leukemia/Lymphoma, Others), HLA Typing, Sperm Analysis, Cell Cycle Kinetics, Cell Function Testing, Chromosomal Abnormalities, Fetal Cell Analysis, Granulocyte Function, Receptor DNA/RNA Analysis, Cell Culturing.
Sales and Market Share Analysis
- Sales and market shares of major instrument and reagent suppliers.
Geographic Coverage
France, Germany, Italy, Japan, Spain, UK, USACompetitive Assessments
- Extensive strategic profiles of major suppliers and emerging market entrants.
Market Segmentation Analysis
- Sales and market share estimates for leading suppliers of hematology and flow cytometry products by country.
- Test and sales forecasts for over 40 procedures by country, individual test and market segment:
- Hospitals
- Commercial/Private Laboratories
- Ambulatory Care Centers
- Physician Offices/Group Practices
Current and Emerging Products
- Analysis of current and emerging hematology and flow cytometry tests
- Reagent and instrument sales forecasts by market segment
- Instrument placements and installed base by manufacturer and model
- Sales and market shares of reagent and instrument suppliers
Technology Review
- Assessment of current and emerging technologies, and their potential market applications.
- Comprehensive lists of companies developing or marketing new technologies and products by test.
Worldwide Market Overview
- Facilities performing hematology and flow cytometry testing by country.
- Test volume and sales projections by country.
Strategic Recommendations
- New product development opportunities with significant market appeal.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
Contains 700 pages and 250 tables
Biomaterials are materials of either synthetic or natural origin that are used for interaction with biological systems for medical purposes such as treating or repairing damage tissues. They are used in joint replacements, plastic surgeries, drug delivery devi...
The global DNA sequencing market was estimated to be $6,243 million in 2017 and is projected to reach $25,470 million in 2025 growing with a CAGR of 19% from 2018 to 2025. DNA sequencing is a type of technology in which several DNA strands can be sequenced through massive parallelization. The DNA sequencing contains both Sanger’s method of sequencing and non-Sanger’s methods of sequencing. ...
Patients with serious nervous system injuries or strokes often require lifelong assistance, which burdens patients, their families, and society. Innovative, paradigm shifting strategies are required to develop treatments for neurological injury. Early dia...